

FOR IMMEDIATE RELEASE

**Corporate Inquiries:**  
Susan Brady  
Microbia, Inc.  
617|621-8304  
sbrady@microbia.com

**Media Inquiries:**  
Danielle Whitney  
Biosector2  
212|845-5611  
dwhitney@biosector2.com

## GEORGE CONRADES JOINS MICROBIA BOARD OF DIRECTORS

— Executive Chairman of Akamai —

*CAMBRIDGE, Mass., April 6, 2006*—Microbia, Inc. today announced that George Conrades has joined the Company’s board of directors. During his distinguished career, Mr. Conrades has served in leadership roles for both Fortune 50 enterprises and entrepreneurial start-up companies. He is currently Executive Chairman of Akamai Technologies, Inc. and was Akamai’s first CEO from 1999 to 2005. Under his direction, Akamai grew annual revenues and reached profitability while achieving a position of market leadership. Previously, Mr. Conrades was CEO of BBN, an advanced technology research and development company, and earlier was a senior vice president and member of IBM’s Corporate Management Board. He held a variety of leadership positions during his 31-year career at IBM, including leading IBM United States and IBM Asia/Pacific.

“We are thrilled to integrate George Conrades’ remarkable experience building thriving, enduring businesses into Microbia’s board dynamic,” said Peter Hecht, CEO of Microbia. “George’s unique ability to leverage the capture, flow and communication of information to optimally serve customers and build product markets will be of great value as we refine our strategy for commercializing our therapeutic candidates and deliver our products to the market.”

In addition to his Microbia directorship, Mr. Conrades serves on the boards of directors for Harley-Davidson, Cardinal Health, and BBN Technologies. He is also on the board of trustees for The Scripps Research Institute and Ohio Wesleyan University. Mr. Conrades is a fellow of the American Academy of Arts and Sciences and is a venture partner at Polaris Venture Partners.

“I am very excited to join Peter Hecht and his innovative executive team at Microbia in their quest to build a leading pharmaceutical company,” said Mr. Conrades. “They have attracted terrific scientists and are off to a strong start in developing important medicines and business partnerships. It’s a privilege and important responsibility to be a member of the board of this promising company.”

### About Microbia

Microbia ([www.microbia.com](http://www.microbia.com)) is an entrepreneurial pharmaceutical company dedicated to the science and art of great drugmaking. Two of the Company’s drug candidates are in clinical studies—

MD-1100 for the treatment of constipation-predominant irritable bowel syndrome and other gastrointestinal disorders, and MD-0727 for the treatment of hypercholesterolemia. Microbia's Precision Engineering® business unit collaborates with leading pharmaceutical and chemical manufacturers to improve efficiencies of existing fermentation processes or to create new bioprocesses. Microbia has raised \$174 million in private equity financing and is located in Cambridge, Massachusetts.

###